摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole

中文名称
——
中文别名
——
英文名称
5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole
英文别名
5-(4-Methoxyphenyl)-3-phenoxycarbonylaminopyrazole;phenyl N-[5-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbamate
5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole化学式
CAS
——
化学式
C17H15N3O3
mdl
——
分子量
309.324
InChiKey
YFQAVEHQFPRUNY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    76.2
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-[2-(哌嗪-1-基)]甲基磺酰胺盐酸盐5-(4-methoxyphenyl)-3-phenoxycarbonyl-aminopyrazole三乙胺 作用下, 以 氯仿 为溶剂, 反应 1.0h, 以50 mg的产率得到
    参考文献:
    名称:
    Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives
    摘要:
    A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2006.07.023
  • 作为产物:
    参考文献:
    名称:
    Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives
    摘要:
    A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2006.07.023
点击查看最新优质反应信息

文献信息

  • Urea derivatives
    申请人:Banyu Pharmaceutical Co., Ltd.
    公开号:US06043246A1
    公开(公告)日:2000-03-28
    The present invention relates to a compound represented by the general formula [I]: ##STR1## wherein A represents a nitrogen atom or a group represented by C--R.sup.5 ; Ar.sup.1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar.sup.2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R.sup.1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R.sup.5 ; R.sup.2 represents a hydrogen atom or a lower alkyl group; R.sup.3 and R.sup.4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R.sup.3 and R.sup.4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R.sup.5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R.sup.1, or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.
    本发明涉及一种由通式[I]表示的化合物:##STR1## 其中A代表氮原子或由C-R.sup.5表示的基团; Ar.sup.1代表芳基基团,可以具有从卤原子和较低的烷基和卤代烷基组成的取代基; Ar.sup.2代表芳基或杂环芳基,可以具有从卤原子和较低的烷基,较低的烯基,较低的卤代烷基,较低的烷氧基,较低的烷硫基,较低的烷基氨基,较低的二烷基氨基和芳基组成的取代基; R.sup.1代表氢原子,较低的烷基或通过与R.sup.5连接形成的键; R.sup.2代表氢原子或较低的烷基; R.sup.3和R.sup.4可以相同也可以不同,每个代表氢原子或较低的烷基,或R.sup.3和R.sup.4连接在一起形成含有2到4个碳原子的烷基,可以具有较低的烷基; R.sup.5代表氢原子或羟基,较低的烷基或较低的烷氧基,或通过与R.sup.1连接形成的键,或其盐,其制备方法以及作为活性成分的治疗暴食症、肥胖症或糖尿病的药剂。
  • NOVEL UREA DERIVATIVES
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP0955293A1
    公开(公告)日:1999-11-10
    The present invention relates to a compound represented by the general formula [I]: wherein A represents a nitrogen atom or a group represented by C-R5; Ar1 represents an aryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl and lower haloalkyl groups; Ar2 represents an aryl or heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and lower alkyl, lower alkenyl, lower haloalkyl, lower alkoxy, lower alkylthio, lower alkylamino, lower dialkylamino and aryl groups; R1 represents a hydrogen atom, a lower alkyl group or a bond formed by linking to R5; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and each represents a hydrogen atom or a lower alkyl group, or R3 and R4 are linked to each other to form an alkylene group containing 2 to 4 carbon atoms which may have a lower alkyl group; and R5 represents a hydrogen atom or a hydroxyl, lower alkyl or lower alkoxy group or a bond formed by linking to R1, or its salt, a process for its preparation and an agent for the treatment of bulimia, obesity or diabetes comprising it as an active ingredient.
    本发明涉及通式[I]所代表的化合物: 其中A代表氮原子或由C-R5代表的基团;Ar1代表芳基,其取代基可选自卤素原子和低级烷基及低级卤代烷基组成的组;Ar2代表芳基或杂芳基,其取代基可选自卤素原子和低级烷基、低级烯基、低级卤代烷基、低级烷氧基、低级烷硫基、低级烷基氨基、低级二烷基氨基和芳基组成的组;R1 代表氢原子、低级烷基或与 R5 连接形成的键;R2 代表氢原子或低级烷基;R3 和 R4 可以相同或不同,且各自代表氢原子或低级烷基,或 R3 和 R4 相互连接形成含 2 至 4 个碳原子的亚烷基,该亚烷基可能具有低级烷基;以及 R5 代表氢原子或羟基、低级烷基或低级烷氧基或与 R1 连接形成的键、 或其盐类,其制备方法和治疗贪食症、肥胖症或糖尿病的制剂,其活性成分包括它。
  • UREA DERIVATIVES
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP0955293B1
    公开(公告)日:2003-03-19
  • US6043246A
    申请人:——
    公开号:US6043246A
    公开(公告)日:2000-03-28
  • Novel potent neuropeptide Y Y5 receptor antagonists: Synthesis and structure–activity relationships of phenylpiperazine derivatives
    作者:Toshiyuki Takahashi、Aya Sakuraba、Tomoko Hirohashi、Takunobu Shibata、Masaaki Hirose、Yuji Haga、Katsumasa Nonoshita、Tetsuya Kanno、Junko Ito、Hisashi Iwaasa、Akio Kanatani、Takehiro Fukami、Nagaaki Sato
    DOI:10.1016/j.bmc.2006.07.023
    日期:2006.11
    A series of phenylpiperazine derivatives were synthesized and evaluated for their neuropeptide Y (NPY) Y5 receptor antagonistic activities. The benzindane portion of 2 was replaced by I-phenylpiperazine, resulting in novel urea derivative X Subsequent optimization of the phenylpiperazine template by substitution of the phenyl moiety resulted in a series of (2-methanesulfonamidephenyl)piperazine derivatives that showed potent binding affinity and antagonistic activity for the Y5 receptor. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺